The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction

Heart

Volumn 84, Issue 2, 2000, Pages 142-148

  Chareonthaitawee, P ^a   Gibbons, R J ^a   Roberts, R S ^b   Christian, T F ^a   Burns, R ^c   Yusuf, S ^d  

^a MAYO CLINIC   (United States)

^b Hamilton Civic   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Infarct size; Myocardial infarction; Thrombolysis

Indexed keywords

POLOXAMER; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

EID: 0033863726     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.2.142     Document Type: Article

References (38)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
2. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death, II: transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.
3. Reimer KA, Heide RSV, Richard VJ. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental animal models. Am J Cardiol 1993;72: 13-21G.
4. Kennedy JW, Martin GV, Davis KB, et al. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomised Trial. Circulation 1988;77:345-52.
5. Raitt MH, Maynard C, Wagner G, et al. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996;93:48-53.
6. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase vs streptokinase and heparin vs no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
7. Newby LK, Rutsch WR, Califf RM, et al. for the GUSTO-I Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-55.
8. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
9. Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 1998;31:1246-51.
10. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 1992;86:81-90.
11. Ritchie JL, Cerqueira M, Maynard C, et al. Ventricular function and infarct size: the Western Washington intravenous streptokinase in myocardial infarction trial. J Am Coll Cardiol 1988;11:689-97.
12. Weaver WD, Cerqueira M, Hallstrom AP, et al, for the Myocardial Infarction Triage and Intervention Project Group. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the myocardial infarction triage and intervention trial. JAMA 1993;270:1211-16.
13. Linderer T, Schröder R, Arntz R, et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993;22:1304-10.
14. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-201.
15. Gibbons RJ, Verani MS, Behrenbeck T, et al. Feasibility of tomographic Tc-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of acute treatment in myocardial infarction. Circulation 1989;80:1277-86.
16. O'Connor MK, Hammell TC, Gibbons RJ. In vitro validation of a simple tomographic technique for estimation of percent myocardium "at risk" following adminstration of Tc-99m isonitrile. Eur J Nucl Med 1990;17:69-76.
17. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
18. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm -paradox or predictable? Circulation 1993;88:296-305.
19. Verani MS, Jeroudi MO, Mahmarian JJ, et al. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. J Am Coll Cardiol 1988;12:1573-81.
20. Christian TF, Behrenbeck T, Pellika PA, et al. Mismatch of left ventricular function and infarct size demonstrated by technetium-99m isonitrile imaging after reperfusion therapy for acute myocardial infarction: identification of myocardial stunning and hyperkinesia. J Am Coll Cardiol 1990;16:1632-8.
21. Udelson JE, Coleman PS, Metherall J. Predicting recovery of severe regional dysfunction: comparison of resting scintigraphy with 201-Tl and 99m-Tc sestamibi. Circulation 1994;89:2552-61.
22. Callahan RJ, Froelich JW, McKusick KA, et al. A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication. J Nucl Med 1982;23: 315-18.
23. Burns RJ, Druck MN, Woodward DS, et al. Repeatability of estimates of left-ventricular volume from blood pool counts. J Nucl Med 1983;24:775-81.
24. Lowe JE, Reimer KA, Jennings RB. Experimental infarct size as a function of the amount of myocardium at risk. Am J Pathol 1978;90:363-79.
25. Judgett BI, Hutchins GM, Bulkley BH, et al. Myocardial infarction in the conscious dog: three-dimensional mapping of infarct, collateral flow and region at risk. Circulation 1979;60:1141-50.
26. Reimer KA, Ideker RE, Jennnings RB. Effect of coronary occlusion site on ischemic bed size and collateral blood flow in dogs. Cardiovasc Res 1981;15:668-74.
27. Feiring AJ, Johnson MR, Kioschos JM, et al. The importance of the determination of the myocardial area at risk in the evaluation of the outcome of acute myocardial infarction in patients. Circulation 1987;75:980-7.
28. Christian TF, Gibbons RJ, Gersh BJ. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol 1991;17:1303-8.
29. Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators. Predictors of 30-day murtalily in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91: 1059-68.
30. The GUSTO investigators. An international randomized trial comparing four thrombolytic srategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
31. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
32. Kennedy JW, Ritchie JL, Davis KB, et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983;309:1477-82.
33. Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987;75:817-29.
34. Dalen JE, Gore JM, Braunwald E, et al, and the TIMI Investigators. Six-and twelve-month follow-up of the phase I thrombolysis in myocardial infarction (TIMI) trial. Am J Cardiol 1988;62:179-85.
35. Stadius ML, Davis K, Maynard C, et al. Risk stratification for a year survival based on characteristics identified in the early hours of acute myocardial infarction. Circulation 1986;74:703-11.
36. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1989;i:1367-8.
37. Timm TC, Ross R, McKendall GR, et al. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: a report from TIMI II [abstract]. Circulation 1991;84(suppl 2):II-230.
38. O'Keefe JH, Grines CL, DeWood MA, et al. Factors influencing myocardial salvage with primary angioplasty. J Nucl Cardiol 1995;2:35-41.